- Home
- ANL vs MGLD Comparison
ANL vs MGLD Comparison
Compare ANL & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | ANL | MGLD |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Finance/Investors Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 44.8M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANL | MGLD |
|---|---|---|
| Price | $1.50 | $0.97 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.5K | 13.4K |
| Earning Date | 04-20-2026 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $29,207,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $0.64 |
| 52 Week High | $2.99 | $2.10 |
Technical Indicators
Market Signals| Indicator | ANL | MGLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 44.33 |
| Support Level | $0.88 | $0.91 |
| Resistance Level | $1.59 | $1.09 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.73 | 14.33 |
Price Performance
Historical Comparison ANL
MGLD
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.